Published in J Subst Abuse Treat on April 20, 2017
Development of a Clinically-Viable Heroin Vaccine. J Am Chem Soc (2017) 0.75
New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis (1985) 9.12
Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART). J Exp Psychol Appl (2002) 7.26
Area under the curve as a measure of discounting. J Exp Anal Behav (2001) 6.48
An algorithm for identifying nonsystematic delay-discounting data. Exp Clin Psychopharmacol (2008) 2.34
Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. JAMA (2015) 2.14
Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med (2013) 1.69
Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Drug Alcohol Depend (1996) 1.54
Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend (2011) 1.21
Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J (2010) 1.15
Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol (2005) 1.14
The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend (2011) 1.14
Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol (2012) 1.13
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med (2016) 1.07
Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry (2015) 1.02
Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J Clin Psychiatry (2010) 0.99
A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat (2014) 0.97
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend (2011) 0.95
The Therapeutic Utility of Employment in Treating Drug Addiction: Science to Application. Transl Issues Psychol Sci (2016) 0.89
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend (2015) 0.87
Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res (2008) 0.86
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. J Subst Abuse Treat (2016) 0.85
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend (2014) 0.84
A demonstration project implementing extended-release naltrexone in Los Angeles County. Subst Abus (2015) 0.81
Delay discounting, treatment motivation and treatment retention among substance-dependent individuals attending an in inpatient detoxification program. J Subst Abuse Treat (2014) 0.80
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri. J Subst Abuse Treat (2016) 0.78
Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study. J Subst Abuse Treat (2016) 0.75